XBIO: xeneticbio.com Company Sales Volume

Corporate emblem and logo of Xenetic Bio (XBIO)

Risks associated with early testing of solid tumors necessitate strict austerity, yet the product rollout schedule for Xenetic Biosciences (XBIO) demonstrates business resilience. The value of 0.00 reflects the metric's balance against licensing payments to pharma behemoths, which generate a passive income stream. At the same time, the capital intensity of R&D and regulatory pressure create significant barriers to the development of Xenetic Biosciences (XBIO) within the oncotherapy sector.

XBIO Xenetic Biosciences, Inc.: Company Revenue in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for Xenetic Biosciences Inc. (XBIO)

- market price and analyst price targets:
Summary company analysis:Xenetic Biosciences
Original product of Xenetic Biosciences, Inc.

This metric represents the aggregate of all daily commercial receipts, allowing for an assessment of real cash flow dynamics and the identification of hidden risks during price stagnation. Analyzing the sales time series for Xenetic Biosciences (XBIO) helps optimize the portfolio before drawdowns occur, which is critical for Xenetic Biosciences (XBIO) as margins are declining due to delays in bringing the patented PolyXen and DNase developments to market.

Key competitors

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Total Revenue|OSTX: Company Sales|Company Sales Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Revenue|ANL: Company Total Sales|VERU (Veru Corporation) - Revenue and Sales Volume|Company Total Revenue Tempest Therapeutics, Inc. TPST|Revenue and Sales Volume XLO|Renovaro - Company Sales Volume|Company Revenue Mural Bio MURA|KAPA: Company Sales Volume|OnKure Therapeutics - Revenue and Sales Volume|Company Gross Revenue w2.cytomed.sg GDTC|CRIS: Revenue and Sales Volume|Company Sales Apollomics Inc.|THAR (Tharimmune Corporation) - Revenue and Sales Volume|Revenue and Sales Volume Advanced Biomed Inc|Revenue and Sales Volume GNPX|Company Sales Calidi Biotherapeutics Inc. CLDI|Company Revenue Sunshine Biopharma Inc. SBFM|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue